RSS Feed for Biotech, Pharmaceutical and Clinical Research News | BioSpace (Generated by New Sloth)
Updated: 1 day 5 hours ago
Thu, 04/18/2024 - 02:00
Bioversity Program Preps Grads for Early-Career Life Science Roles 4/18/2024
Thu, 04/18/2024 - 02:00
How to Deal With Layoff-Related Stress 4/18/2024
Thu, 04/18/2024 - 02:00
Career Coach: How to Look Professional in Virtual Meetings 4/18/2024
Thu, 04/18/2024 - 02:00
5 Top Companies Hiring Oncology Jobs 4/18/2024
Wed, 04/17/2024 - 02:00
Lilly Eyes Zepbound Label Expansion After Clearing Phase III Sleep Apnea Study 4/17/2024
Wed, 04/17/2024 - 02:00
Sage Axes Parkinson’s Program for Dalzanemdor After Phase II Flop 4/17/2024
Wed, 04/17/2024 - 02:00
Amylyx Sheds More Light on Relyvrio’s Late-Stage Trial Failure in ALS 4/17/2024
Wed, 04/17/2024 - 02:00
Amylyx at a Crossroads: Can the Company Overcome the Loss of Relyvrio? 4/17/2024
Wed, 04/17/2024 - 02:00
Arvinas Strikes Deals With Pfizer, Novartis to Compete in Protein Degrader Space 4/17/2024
Wed, 04/17/2024 - 02:00
Top Q1 Series A Investments Highlight VC Rebound in Biopharma 4/17/2024
Wed, 04/17/2024 - 02:00
Canaan Secures More Than $100M in New Biopharma Funding, Adds Former Pfizer Executive 4/17/2024
Wed, 04/17/2024 - 02:00
Cullinan Targets Autoimmune Market, Nabs $280M in Private Placement 4/17/2024
Wed, 04/17/2024 - 02:00
GSK Touts Late-Stage Antibiotic Win in Gonorrhea, Long-Term Shingrix Vaccine Data 4/17/2024
Wed, 04/17/2024 - 02:00
Arrowhead’s Plozasiran Poised for Dyslipidemia Market, $700M in Sales by 2032: GlobalData 4/17/2024
Wed, 04/17/2024 - 02:00
Amylyx and ALS, Continued ADC Excitement, Dire Drug Shortages 4/17/2024
Wed, 04/17/2024 - 02:00
C-Suite Shuffle: Bayer Continues Leadership Shakeup with Hires at Subsidiaries 4/17/2024
Tue, 04/16/2024 - 02:00
J&J Narrowly Misses Q1 Revenue on Lower-Than-Expected Stelara Sales 4/16/2024
Tue, 04/16/2024 - 02:00
Sandoz’s Biosimilar Skyrockets After CVS Removes AbbVie’s Humira from Formularies 4/16/2024
Tue, 04/16/2024 - 02:00
Boehringer Ingelheim Aims to Bring 25 New Products to Market by 2030 4/16/2024
Tue, 04/16/2024 - 02:00
Novartis Secures Phase III Fabhalta Win in IgAN as FDA Starts Priority Review 4/16/2024